Skip to main content

Pediatric Clinics 

When their children are sick, anxious parents want answers fast. Pediatric clinicians want diagnostic results that enable timely, informed treatment decisions—and get kids back to being kids. 

Pediatric Onsite Infectious Disease Testing

Being able to determine a causative pathogen for a child’s infection can help children avoid unnecessary antimicrobials and give parents confidence in a treatment plan. Diagnosing respiratory or gastrointestinal infections based on symptoms alone is difficult, if not impossible. Traditional diagnostic methods are time-consuming and may involve costly send-out tests. Onsite syndromic PCR testing gives clinicians the results they need to make timely, appropriate patient management decisions.


For results that are fast and accurate, the BIOFIRE TORCH uses PCR technology to simultaneously test for a comprehensive grouping of targets in about an hour. For use in CLIA-moderate settings.

BIOFIRE® FILMARRAY® 2.0 EZ Configuration

The BIOFIRE 2.0 EZ facilitates fast, onsite respiratory testing. Designed to be used with the BIOFIRE RP2.1-EZ Panel (EUA) in CLIA-waived settings, the system offers results in ~45 minutes.

BIOFIRE® Respiratory 2.1 Panel

Identify 22 of the most common viral and bacterial respiratory pathogens, including SARS-CoV-2, influenza A and B viruses, RSV, and many others. All in one test, with results in about 45 minutes. Onsite in CLIA-moderate settings.

BIOFIRE® Respiratory 2.1-EZ Panel (EUA)*

Perform in-clinic testing of those suspected of COVID-19. This syndromic panel identifies 19 probable bacterial and viral respiratory targets in one fast and easy test. *Emergency use authorization.

BIOFIRE® FILMARRAY® Gastrointestinal Panel

Test for 22 gastrointestinal pathogens, including bacteria, yeast, and parasites, in one easy-to-perform test—with results in about an hour. Onsite in CLIA-moderate settings.

BIOFIRE® Joint Infection Panel

Overcome the challenges of traditional joint infection testing with a syndromic panel that identifies 31 pathogenic targets and 8 antimicrobial resistance genes—all onsite in CLIA-moderate settings.